Dermatology

These data highlight the risk of anxiety and depression among dermatologists, with notable findings based on gender differences observed among clinicians.

New data suggest children with atopic dermatitis and comorbid ADHD are nearly 3 times more likely to struggle with memory compared to those with just ADHD.

Counting down the most impactful news at major medical meetings, it’s the HCPLive Five! This edition shares 5 important updates from the American Academy of Dermatology (AAD) 2024 meeting.

The results of this analysis highlight the link between patients’ experiences with pruritus intensity and the mental health difficulties such struggles place on patients.

Data show significant maternal and fetal risks in cases when pregnant women are diagnosed with hidradenitis suppurativa. A researcher discusses opportunities to learn more.

Isotretinoin was actually linked to a taller adult height among those who took it to treat acne in childhood versus doxycycline, in a new study.

In this AAD 2024 interview, Bunick highlights several new findings on the use of topical isotretinoin for treatment of congenital ichthyosis.

New data show sensitization among children with allergic contact dermatitis may be significantly influenced by their age and gender, among other demographic details.

Alexis discusses clinical and demographic hurdles in treating skin of color for conditions like atopic dermatitis, and the potential of research like that being done in tapinarof cream 1%.

Dr April W. Armstrong reviews key findings from the phase 3 POETYK PSO-1 and POETYK PSO-2 clinical trials evaluating the use of deucravacitinib for the treatment of plaque psoriasis.

April W. Armstrong, MD, MPH, discusses emerging therapies in oral systemics for the treatment of plaque psoriasis and shares developments in TYK2 inhibition.

Blauvelt discusses the future research of higher-dose risankizumab for patients with psoriasis—and why it may be "disruptive in the treatment space."

New global data suggest children with moderate to severe atopic dermatitis may experience stunted growth due to the effect of their disease on sleep, as well as use of certain therapies.

Gelfand discusses the convenience of phototherapy, and how its efficacy may complement biologic regimens in patients with psoriasis.

These data presented at AAD 2024 highlight deuruxolitinib’s efficacy in the treatment of adults with moderate-to-severe alopecia areata.

New data from the Mayo Clinic show high BMI does not correlate with severe hidradenitis suppurativa in affected children and adolescents.

Blauvelt discusses the impetus for his phase 2 trial looking at the ability to mitigate pivotal psoriasis memory T cells with risankizumab.

In a phase 3 trial that featured approximately half of participants with skin of color, tapinarof cream 1.0% provided consistent benefit for patients identified as White, Black, or Asian.

Kim discusses the state of dermatology innovation and applied care, as well as his involvement in a new company in the space.

In this interview at AAD 2024, Porter discussed her team’s phase 2 findings on hidradenitis suppurativa the impact of ruxolitinib cream among those with Hurley Stage I and II.

Kimball discusses her team’s new late-breaking data regarding the safety and effectiveness of lutikizumab in treating the symptoms of moderate-to-severe HS in adult non-responders to anti-TNF therapy.

A secondary analysis from TRuE-AD3 shows ruxolitinib cream significantly benefits pediatric atopic dermatitis patient-reported outcomes.

These phase 3 findings from AAD 2024 suggest patients treated with baricitinib may continue to see scalp, eyelash, and eyebrow hair regrowth with specific dosing regimens.

Thierry Passeron, MD, PhD, discusses the potential benefit of upadacitinib as an oral systemic therapy in patients with nonsegmental vitiligo.

Data presented at AAD 2024 hopes to clarify allergen exposure risks during infancy that may increase risk of allergic contact dermatitis.

The pioneer in neuroimmune research and itch physiology discusses how treatment innovation has evolved dermatology—and what still needs to be changed in practice.

In this interview at AAD 2024, Porter discusses recent data from the SUNSHINE and SUNRISE trials on secukinumab for patients with HS.

Phototherapy is consistently beneficial for patient-reported and clinical outcomes regardless of the location, according to late-breaking data at AAD 2024.

Data from the phase 2 KNOCKOUT study show risankizumab's sustained benefit in reducing memory cells over 52 weeks in psoriasis patients.

These findings from AAD 2024 did not include statistically significant infliximab response predictors, though it had been the largest reported cohort on the subject to date.